RCS - MaxCyte, Inc. - Participation in Upcoming Investor Conferences
FOR IMMEDIATE RELEASE
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows:
Cowen 41st Annual Health Care Conference
Who: Doug Doerfler, President & Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will present a corporate overview
Dates: Virtual conference March 1 - 4, 2021
MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET
An archived version of the presentation will be made available following the conference in the Investors section of the Company website
H.C. Wainwright & Co Global Life Sciences Conference
Who: Doug Doerfler, President & Chief Executive Officer, will present a corporate overview
Dates: Virtual conference March 9 - 10, 2021
MaxCyte Presentation Details: Available on demand to conference participants March 9 - 10, 2021
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering platform technology and is responsible for helping to bring next‐generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
+1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
Joint Corporate Brokers
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd
+44 (0)20 7260 1000
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
+44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNRAEAEAAAALFEAA
